

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8151)

PROPOSED TRANSFER OF LISTING OF THE SHARES FROM THE GROWTH ENTERPRISE MARKET TO THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED

The Directors are pleased to announce that on 20 April 2011 the Company has made an application to the Stock Exchange for the transfer of listing of all its Shares from GEM to the Main Board.

The board of directors (the “**Board**”) of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that on 20 April 2011, the Company made an application to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for the transfer of listing of all its issued shares of par value of HK\$0.10 each (the “**Shares**”) from the Growth Enterprise Market of the Stock Exchange (“**GEM**”) to the Main Board of the Stock Exchange (the “**Main Board**”) (the “**Transfer of Listing**”) pursuant to the streamlined procedures for transfer of listing under Chapter 9A of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board believes that the Transfer of Listing will improve the liquidity of the Shares and enhance the profile of the Company. The Board considers that the Transfer of Listing will be beneficial to the future growth and business development of the Group as well as its financing flexibility. As at the date of this announcement, the Board has no immediate plan to change the nature of business of the Group following the Transfer of Listing. The Transfer of Listing does not involve any issue of new Shares by the Company.

Shareholders of the Company and potential investors should be aware that the implementation of the Transfer of Listing is subject to, among other things, the granting of relevant approval by the Stock Exchange. Accordingly, the proposed Transfer of Listing may or may not proceed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares.

The Company will make further announcement(s) to keep the shareholders of the Company informed of the progress of the Transfer of Listing.

By order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 20 April 2011

Executive directors of the Company as at the date of this announcement are Dr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.essexbio.com.